Stay updated with breaking news from Affimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on AFMD. Berenberg Bank restated a buy rating and set a $6.00 price objective on shares […]
Shares of Affimed (NASDAQ:AFMD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among […]
Affimed (NASDAQ:AFMD – Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,160,000 shares, a decrease of 8.9% from the September 15th total of 2,370,000 shares. Based on an average daily volume of 485,400 shares, the days-to-cover […]
StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. Truist Financial reduced their target price on Affimed from $8.00 to $6.00 and set a buy […]
StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other equities research analysts have also recently commented on AFMD. Truist Financial lowered their price target on Affimed from $8.00 to $6.00 and set a […]